fluorouracil has been researched along with Adenomatous Polyposis Coli, Familial in 14 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-fluorouracil (5-FU) is the first line component used in colorectal cancer (CRC) therapy however even in combination with other chemotherapeutic drugs recurrence is common." | 3.80 | Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. ( Brocardo, MG; Henderson, BR; Martino-Echarri, E, 2014) |
| "Differently from target-based anticancer drugs, molecular mechanisms of actions are not well-known in many of the classical antineoplastic agents." | 2.44 | [DNA repair as a determinant of tumour chemosensitivity]. ( Kuraoka, I; Maehara, Y; Oda, S, 2007) |
| "Truncating mutations in adenomatous polyposis coli (APC) are well-described events in CRC carcinogenesis." | 1.56 | APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy. ( Abduljabbar, A; Ahmed, SO; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Ashari, LH; Begum, R; Concepcion, RMJA; Kumar Parvathareddy, S; Melosantos, R; Padmaja Divya, S; Pratheeshkumar, P; Siraj, AK, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Siraj, AK | 1 |
| Kumar Parvathareddy, S | 1 |
| Pratheeshkumar, P | 1 |
| Padmaja Divya, S | 1 |
| Ahmed, SO | 1 |
| Melosantos, R | 1 |
| Begum, R | 1 |
| Concepcion, RMJA | 1 |
| Al-Sanea, N | 1 |
| Ashari, LH | 1 |
| Abduljabbar, A | 1 |
| Al-Dayel, F | 1 |
| Al-Kuraya, KS | 1 |
| Pardillos Tomé, A | 1 |
| Bajador Andreu, E | 1 |
| Comín Orce, A | 1 |
| Marcilla Córdoba, F | 1 |
| Han, Y | 1 |
| Cai, H | 1 |
| Ma, L | 1 |
| Ding, Y | 1 |
| Tan, X | 1 |
| Liu, Y | 1 |
| Su, T | 1 |
| Yu, Y | 1 |
| Chang, W | 1 |
| Zhang, H | 1 |
| Fu, C | 1 |
| Cao, G | 1 |
| Martino-Echarri, E | 1 |
| Henderson, BR | 1 |
| Brocardo, MG | 1 |
| Lombardo, Y | 1 |
| Scopelliti, A | 1 |
| Cammareri, P | 1 |
| Todaro, M | 1 |
| Iovino, F | 1 |
| Ricci-Vitiani, L | 1 |
| Gulotta, G | 1 |
| Dieli, F | 1 |
| de Maria, R | 1 |
| Stassi, G | 1 |
| Costa, LA | 1 |
| Cezana, L | 1 |
| Oliveira, TB | 1 |
| Dettino, AL | 1 |
| Begnami, MD | 1 |
| Pinto, CA | 1 |
| Fanelli, MF | 1 |
| Mello, CA | 1 |
| Pioche, M | 1 |
| Aguero Garcete, G | 1 |
| Forestier, J | 1 |
| Lépilliez, V | 1 |
| Nozières, C | 1 |
| Lombard-Bohas, C | 1 |
| Saurin, JC | 1 |
| Jones, DH | 1 |
| Silberstein, PT | 1 |
| Lynch, H | 1 |
| Ternet, C | 1 |
| Oda, S | 1 |
| Kuraoka, I | 1 |
| Maehara, Y | 1 |
| Ishii, Y | 1 |
| Wakayama, H | 1 |
| Nakayama, K | 1 |
| Ami, K | 1 |
| Iida, M | 2 |
| Hotta, M | 1 |
| Oota, K | 1 |
| Yamazaki, S | 1 |
| Takahashi, M | 1 |
| Ichikawa, D | 1 |
| Takahashi, T | 1 |
| Adachi, T | 1 |
| Kimura, A | 1 |
| Shirasu, M | 1 |
| Matsumoto, H | 1 |
| Kitamura, K | 1 |
| Yamane, T | 1 |
| Yamaguchi, T | 1 |
| Staines, A | 1 |
| Cullen, S | 1 |
| Guiney, EJ | 1 |
| Fitzgerald, RJ | 1 |
| Breatnach, F | 1 |
| Itoh, H | 1 |
| Mibu, R | 1 |
| Terasaka, R | 1 |
| Ohsato, K | 1 |
| Koyama, S | 1 |
| Tatsumura, T | 1 |
| Ishizaka, S | 1 |
| Miyazaki, M | 1 |
| Tsuda, M | 1 |
| Sato, H | 1 |
| Mori, A | 1 |
| Yamamoto, K | 1 |
2 reviews available for fluorouracil and Adenomatous Polyposis Coli, Familial
| Article | Year |
|---|---|
[DNA repair as a determinant of tumour chemosensitivity].
Topics: Adenomatous Polyposis Coli; Antineoplastic Agents; Cisplatin; DNA; DNA Mismatch Repair; DNA Repair; | 2007 |
[Postoperative management of the preserved rectal segment in patients with familial polyposis: the use of 5-fluorouracil suppositories and green tea extract to inhibit tumor growth].
Topics: Adenomatous Polyposis Coli; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Plant Extracts; P | 1998 |
12 other studies available for fluorouracil and Adenomatous Polyposis Coli, Familial
| Article | Year |
|---|---|
APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy.
Topics: Adenomatous Polyposis Coli; Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neop | 2020 |
Familial adenomatous polyposis associated with pancreatic neuroendocrine tumour.
Topics: Adenomatous Polyposis Coli; Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Colonic | 2021 |
Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biom | 2013 |
Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy.
Topics: Adenomatous Polyposis Coli; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2014 |
Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.
Topics: AC133 Antigen; Adenomatous Polyposis Coli; Aged; Aged, 80 and over; Animals; Antigens, CD; Antineopl | 2011 |
Successful treatment of an intra-abdominal desmoid tumor with irinotecan, fluorouracil, and leucovorin plus bevacizumab in a patient with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineo | 2012 |
Macroscopic and histologic regression of duodenal polyposis with FOLFOX4 chemotherapy for an ileal pouch adenocarcinoma in a patient with familial adenomatous polyposis.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2005 |
[A case of hepatic metastasis of rectal cancer with familial adenomatous polyposis treated by transarterial administration of low-dose leucovorin and 5-FU].
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 1998 |
Combination chemotherapy in the treatment of hepatoblastoma.
Topics: Adenomatous Polyposis Coli; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biom | 1990 |
Local chemotherapy for rectal polyposis: intraluminal administration of 5-fluorouracil for postoperative control of adenomas in the retained rectum in familial polyposis.
Topics: Adenomatous Polyposis Coli; Administration, Rectal; Adult; Colectomy; Combined Modality Therapy; Ene | 1989 |
[The efficacy of temporary retention chemotherapy of the treatment of polyps in the remnant rectum of familial polyposis after total colectomy and ileorectostomy--a case report].
Topics: Adenomatous Polyposis Coli; Adult; Colectomy; Combined Modality Therapy; Female; Fluorouracil; Human | 1987 |